Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Eliot N. Mostow MD, MPH Associate Editor

Robert T. Brodell MD, FAAD Editor-in-Chief

Ashish C. Bhatia MD, FAAD Associate Editor

See All Experts

featured

Published in Dermatology

Journal Scan / Research · October 06, 2016

Secukinumab Is Superior to Ustekinumab in Clearing Moderate to Severe Plaque Psoriasis Up to 1 Year

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Andrew Blauvelt MD, MBA

Journal of the American Academy of Dermatology

Secukinumab Is Superior to Ustekinumab in Clearing Skin of Subjects With Moderate-to-Severe Plaque Psoriasis Up to 1 Year: Results From the CLEAR Study

J Am Acad Dermatol 2016 Sep 20;[EPub Ahead of Print], A Blauvelt, K Reich, TF Tsai, S Tyring, F Vanaclocha, K Kingo, M Ziv, A Pinter, R Vender, S Hugot, R You, M Milutinovic, D Thaçi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Secukinumab Is Superior to Ustekinumab in Clearing Moderate to Severe Plaque Psoriasis Up to 1 Year

Additional Info

Secukinumab Is Superior to Ustekinumab in Clearing Skin of Subjects With Moderate-to-Severe Plaque Psoriasis Up to 1 Year: Results From the CLEAR Study

Further Reading

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Safety of Biologic Use During Pregnancy and Breastfeeding in Dermatology

Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Efficacy of Treatment With Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis Through 76 Weeks

Non-SCORTEN Predictors of Mortality Among Patients With SJS/TEN

Risk Factors for Subclinical Spread in Patients With Melanoma In Situ and Invasive Melanoma

Outcomes of Dermoscopic vs Naked-Eye Evaluation of Surgical Margins in Patients With Nonmelanoma Skin Cancer Undergoing Mohs Micrographic Surgery

Recently Updated